Celltrion posts record Q1 earnings on strong biosimilar sales

Celltrion said Wednesday it posted record first-quarter results, with consolidated revenue of over 1.14 trillion won ($783 million) and operating profit of 321.9 billion won. Revenue rose 36 percent on-year, while operating profit surged 115.5 percent, with the operating margin improving to 28.1 percent. All 11 biosimilar products currently on the market maintained stable revenue streams, while high-margin new products drove growth, with sales from the segment jumping 67 percent on-year. These n

By The Korea Herald